In most cases, recording a symptom score helps to make the diagnosis. Checking a follicle-stimulating hormone level or serum oestradiol and progesterone are unnecessary tests in diagnosing menopause, and androgen profiles as a routine on all peri-menopausal women are not indicated. [5] Age and time since menopause affect the balance of benefits and risks for hormone therapy (HT) use in post-menopausal women. [6] Observational studies revealed the positive role of Homoeopathy in alleviating the menopausal complaints and improving quality of life. [7] [8] [9] An audit report of National Health Service community menopause clinic through homoeopathic intervention suggested greatest response in those patients who reported headaches, vasomotor symptoms, emotional or psychological symptoms and tiredness or fatigue, respectively, as their primary symptoms. [10] Randomised-controlled trials (RCTs) on Homoeopathy for menopausal symptoms and oestrogen withdrawal symptoms in breast cancer survivors did not show statistically significant results. [11, 12] In another RCT on moderate to severe depression in peri-and post-menopausal women, individualised Homoeopathy was not only effective for depression but also improved menopause symptoms according to Greene Climacteric Scale (GCS) whereas Fluoxetine was not different from placebo in alleviating menopausal complaints. [13] In an RCT on hot flushes induced by adjuvant endocrine therapy in localised breast cancer patients, Homoeopathy alleviated the hot flushes-related disabling symptoms, providing an interesting support for better adherence to endocrine therapy, thereby reducing the risk of recurrence. There was also a positive impact on QOL. [14] Based on the promising results of Central Council for Research in Homoeopathy's previous study, [15] wherein Sepia was indicated and prescribed in maximum number of cases (n = 53), of which 37 patients observed marked improvement, 14 had moderate improvement and 2 had mild improvement, this study was planned to further validate Sepia as drug having efficacy in the management of menopausal symptoms. This randomised double-blind placebo-controlled study was designed with an objective to compare the efficacy of Sepia against placebo in such a manner that the prescribing indications of Sepia are available in both the groups (Sepia and control).
MateRIals and Methods

Study design
The study was a multicentric, randomised, double-blind placebo-controlled with a 6-month intervention and follow-up period.
Study setting
The study was conducted at Regional Research Institute for Homoeopathy, Puri (Odhisa); Regional Research Institute for Homoeopathy, Mumbai (Maharashtra); Clinical Research Unit in Homoeopathy, Siliguri (West Bengal) and Dr. D. P. Rastogi Central Research Institute for Homoeopathy, Noida (Uttar Pradesh).
Data collection
The study was conducted from April 2012 to September 2014. Each case was followed up for 6 months to assess the outcome of the treatment. Study data were collected at baseline, every follow-up (monthly or earlier if required) and at final/termination visit. The patients were evaluated for symptomatic and clinical assessment, laboratory parameters and adverse events, if any, as per the study protocol.
Randomisation
Same set of random numbers were generated for the four study sites. Each patient was assigned either Series 1 or Series 2 as intervention through random numbers obtained from www. randomizer.org. [16] All eligible patients were randomised to either 'Series I' or 'Series II' to receive Sepia or identical placebo. Patients and physicians both were blinded in the entire process.
Participants
The inclusion criteria for study participants were as follows:
(1) perimenopausal women between 40 and 55 years of age with a history of menopausal symptoms for at least 1 month within the last one year, (2) signed the informed consent form (written consent was taken before detailed case taking to provide observational data and have their data used comparatively), (3) women presenting with indications for medicine -Sepia as per homoeopathic literature and (4) if the patient was under any treatment for the menopausal complaints or taking oral contraceptives, she was included only after the washout period of 15 days. In case, the patient was on hormone replacement therapy (HRT), she should have withdrawn HRT for at least 2 months before inclusion.
The exclusion criteria included (1) women with established menopause, either natural or artificial; (2) dysfunctional uterine bleeding/history of endometrial hyperplasia or malignancy; (3) women on long-term medication for any disease; (4) women with a history of severe psychiatric disturbance; (5) women with a history of systemic illnesses, hypertension, diabetes mellitus, cardio-or cerebro-vascular diseases, pelvic pathology requiring surgery or any malignancy and (6) women using any medicine or supplement containing oestrogen and progestin.
The patients were screened for eligibility. Routine examination and investigations including general, systemic and gynaecological examinations (per speculum, per vaginal, if required); complete haemogram; blood sugar fasting and post prandial; lipid profile, kidney function test and liver function test; urine and stool for routine and microscopical examination; ultrasonography of whole abdomen; Papanicolaou test smear if the patients agreed and mammography were done before enrollment.
All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Declaration of Helsinki [17] of 1975 and Good Clinical Practices -India. [15] 
Intervention
Homoeopathic medicine -Sepia 200 C procured from Good Manufacturing Practices compliant-licensed homoeopathic pharmaceutical company. Sepia or identical placebo were prescribed in 200 C at monthly interval.
Criteria for baseline assessment and follow-up
Assessment of menopausal symptoms of all enrolled cases was taken up as per 'The GCS' (primary outcome measure) at baseline and each month for 6 months. Quality of life was also assessed using Utian Quality of Life (UQOL) scale (secondary outcome measure) [18] at baseline and at 6 months. The investigations which were out of range at baseline were repeated at the end of the treatment. Indian Journal of Research in Homoeopathy ¦ Volume 13 ¦ Issue 4 ¦ October-December 2019 
Outcomes
The outcomes were the changes in the menopausal complaints assessed using GCS and UQOL scales. The Greene Scale provides a brief measure of menopause symptoms. Severity of the problem is scored from 0 (none), 1 (mild), 2 (moderate) and 3 (severe) at baseline and on monthly follow-up till 6 months.
Statistical methods
Statistical analysis was done using IBM SPSS version 20.0 (IBP Corp, IBM SPSS statistics for windows, Armonk, NY: IBM corp.). Comparison between Sepia and placebo groups was performed at baseline to assess the randomisation effect using independent t-test. The main outcome measure of GCS changes from baseline to 6 months between groups was done using independent t-test. The UQOL changes from baseline to 6 months of follow-up were also estimated using independent t-test. The data were presented in n (no. of cases), mean ± standard deviation in all the analysis, P < 0.05 was considered statistically significant.
Results
88 participants who had given written informed consent were enrolled according to the inclusion criteria. Flow diagram of the progress through the phases of a RCT of Sepia and placebo (that is, enrollment, intervention, allocation, follow-up and data analysis) is depicted in Figure 1 . Mean age in Sepia group was 46.3 ± 3.9 and in placebo was 45.9 ± 4.2 years. At baseline, the total score of GCS was 30.23 ± 8.1 and 30.05 ± 8.89 in intervention and verum group, respectively, and UQOL score was 59.09 ± 7.74 and 57.39 ± 7.80 in intervention and verum group, respectively, at baseline. Baseline characteristics and the laboratory investigations were comparable in both the groups and statistically insignificant [ Table 1 ].
Symptoms of medicine -Sepia reported by patients at the time of enrollment in both the groups are mentioned cumulatively in Table 2 .
The primary outcome, GCS was reduced from 30.23 ± 8.1 to 7.86 ± 4.6 in Sepia group (improvement of 73.9%) and from 30.05 ± 8.9 to 12.73 ± 8.3 in placebo group (improvement of 57.63%). There was a statistically significant difference between both the groups, when compared after 6 months (P = 0.001) [ Tables 3 and 4 ].
In addition to that, independent t-test has been used for change in mean of GCS from baseline to 6 months [ Table 5 ].
The cases that had baseline score ≥20 (n = 82) indicating high degree of symptoms were also analysed. These 82 cases (Sepia = 42 and placebo = 40) were analysed, and there was a statistically significant difference between the two groups, when compared after 6 months (P = 0.001) [ Table 6 ]. 
dIscussIon
Homoeopathy is a unique therapeutic system, and homoeopathic case management may involve two different types of diagnosis, namely clinical diagnosis -based on the condition and individual diagnosis -based on the symptoms of each single patient.
This study was conducted with the objectives of evaluating the efficacy of Sepia, a well-known medicine indicated in the management of menopausal symptoms. 'The GCS' and 'UQOL' were used to assess the outcome.
The most frequent symptoms on which Sepia was prescribed were irritability (52, 59%), anxiety (32, 36.4%), indifference On analysing the data of patients whose baseline score was either equal to or more than 20, there is a statistically significant difference in reduction of GCS score (P = 0.001) when compared after 6 months indicating positive response with the prescription of Sepia. There is improvement from 2 nd month onwards in Sepia group.
The mean menopausal age of the sample population was 46.3 ± 3.9 years which corroborates with survey undertaken by Indian Menopause Society and found 46.2 ± 4.9 years as the average age. [18] In another observational study by Nayak et al., the mean menopausal age of the sample population was 46.66 years. [15] Therefore, it was felt pertinent to analyse data of patients between the age group (40-50 years) in this study which turned out to be statistically significant.
In another study by Andrade et al., [19] the homoeopathic medicine of Capsicum frutescens (Malagueta) was superior to placebo in reducing the intensity of hot flashes in menopausal women after 4 weeks of treatment.
With respect to secondary objective (to assess the quality of life using UQOL), Homoeopathy showed, however, slightly better quality of life in comparison with placebo after 6 months' follow-up. This could be because the patients belonged to moderate category of symptoms at baseline; therefore, they did not report of marked improvement in quality of life.
'Single remedy' approach has been used by Shipley et al. [20] and Savage and Roe [21] on similar lines.
The limitation of this study was that after selecting Sepia as medicine for patients at baseline, the investigators were supposed to continue the same medicine during follow-up period, which contradicts the routine homoeopathic practice where there could be requirement of change in prescription. It was observed in one of the reviews that, often, in Homoeopathy, it is not possible to find the correct remedy at once and/or change the remedy as the clinical picture changes. In a case of a double-blind trial, a homoeopathic practitioner often encounters the challenges due to any three possibilities, namely, a failure to reach correct similimum, any symptom shift in patients and totality or patient being a participant of a placebo group. [22] In the present study, double-blind, placebo-controlled methodology was adapted, which is the gold standard in conventional medicine for clinical trials using single drug intervention, but it seems that this methodology might be a constraint for achieving the sample size, as large number of patients screening is required, for recruiting/enrolling patients requiring a particular remedy. This challenge is also reported by other researchers. [19, 23] Patients in the placebo group had undergone homoeopathic case history recording procedure that might contribute considerably to a possible treatment effect, decreasing the likelihood of identifying differences between the groups. [24] The biggest problem faced by clinical research in Homoeopathy is that of independent reproducibility. The issue of independent reproducibility was also raised by the publication of a series of studies of homoeopathic therapy of headache. A randomised, double-blind, placebo-controlled clinical trial of the treatment of migraine with the limited range of homoeopathic medicines by Brigo and Serpelloni [25] gave strongly positive result; however, study by Whitmarsh et al. [26] and Walach et al. [27] failed to show any difference between Homoeopathy and placebo, although the two studies were of high methodology quality. [28] Despite all these constraints for clinical trial with double-blind RCT design, this study has shown positive response of homoeopathic medicines in allaying the menopausal symptoms in comparison to placebo within the duration of 6 months.
conclusIon
Sepia is able to allay the menopausal symptoms when prescribed on symptomatic indications as per homoeopathic jtks fuofRr ds y{k.kks a ds iz ca /ku ds fy, gks E;ks iS fFkd nok lhfi;k % ,d cgq &ds a fnz r ;knfPNd Mcy Cykba M Iys flcks fu;a f=r uS nkfud ijh{k.kA mnñs ";% *n xz hu DykbZ es DVs fjd Lds y* ¼thlh,l½ dk mi;ks x djrs gq , lhfi;k }kjk jtks fuofRr ds y{k.kks a dk iz ca /ku vkS j thou dh xq .koRrk ekina M ¼;w D;w vks ,y½ dk mi;ks x djrs gq , thou dh xq .koRrk rFkk gks E;ks iS fFkd fpfdRlk dh iz Hkkodkfjrk dk ew Y;kda uA fof/k% viz S y 2012 ls flra cj 2014 rd ifj'kn~ ds pkj vuq la /kku ds a nz ks a ij ,d ;knfPNd Mcy&Cykba M Iys flcks fu;a f=r uS nkfud v/;;u fd;k x;kA is jh es uks ikW ty ekeyks a dh tka p dh xbZ (n=471) vkS j ekina M ekud (n=88) dks iw jk djus okyks a iz ;ks T;ks a dks fdlh ,d gks E;ks iS fFkd gLr{ks i vFkkZ r ls fi;k (n=44) ;k le#i Iys flcks (n=44) es a ukeka fdr vkS j ;knfPNd fd;k x;k Fkk vkS j mlds ckn iw oZ fu/kkZ fjr uS nkfud ifj. kkeks a ds ew Y;ka du ds fy, Ng eghus rd yxkrkj tka pk x;kA iz kFkfed ifj.kke xz hus Dykbes DVs fjd Lds y ¼thlh,l½ dk mi;ks x djds ew Y;ka du dh xbZ jtks fuofRr dh f"kdk;rks a es a ifjorZ u Fkk vkS j nforh;d ifj.kke es a thou ds ;w Vh,u xq .koRrk ¼;w D;w vks ,y½ iS ekus es a ifjorZ u ik;k x;kA ifj.kke % iz kFkfed ifj.kke fo"ys 'k.k ds fy, 88 jks fx;ks a ij fopkj fd;k x;kA thlh,l dk iz kFkfed ifj.kke eki ;kuh dq y Ldks j ls tc 6 eghus ckn rq yuk dh xbZ ] rks 30.23 ± 8.1 ls 7.86 ± 4.6 rd ?kVk FkkA flfi;k lew g es a lq /kkj 73.9% vkS j 30.05 ± 8.9 ls 12.73 ± 8.3 Iys flcks lew g es a lq /kkj ¼57.63% dk lq /kkj½ ¼ih = 0.001½A Ng eghus ¼ih = 0.001½ ds ckn nks uks a lew gks a ds chp lka f[;dh; #i ls egRoiw .kZ va rj FkkA ek/;fed ifj.kke ds la ca /k es a ] dq y ;w D;w vks ,y Ldks j 59.09 ± 7.74 flfi;k lew g ds fy, vkS j 57.39 ± 7.80 cs lykbu ij Iys flcks lew g ds fy, vkS j 62.43 ± 7.71 flfi;k lew g ds fy, vkS j 63.48 ± 7.53 cs lykbu ij Iys flcks lew g ds fy, thou dh xq .koRrk es a Ng eghus ds ckn ekew yh va rj gS A fu'd'kZ % tc gks E;ks iS fFkd fl)ka rks ds vuq lkj jks xlw pd la ds rks a ds vk/kkj ij nok fu/kkZ fjr dh xbZ ] rks flfi;k] jtks fuofRr ds y{k.kks a dks nw j djus es a l{ke ikbZ xbZ A Médicament homéopathique Sepia pour la gestion des symptômes de la ménopause : essai clinique multicentrique randomisé à double insu contrôlé contre placebo Objectifs : Évaluer l'efficacité du médicament homéopathique, Sepia dans la gestion des symptômes de la ménopause à l'aide de la grille 'The Greene Climacteric Scale' (GCS -échelle climatérique de Greene) et sur la qualité de vie à l'aide de la grille 'Utian Quality of Life Scale' (UQOL -échelle d'Utian sur la qualité de vie). Méthodes : Une étude clinique randomisée à double insu contrôlée contre placebo a été menée d'avril 2012 à septembre 2014 dans quatre centres de recherche du CCRH. Les cas péri-ménopausiques ont été examinés (n = 471) et ceux répondant aux critères d'éligibilité (n = 88) ont été retenus et randomisés pour soit une intervention homéopathique, c'est-à-dire Sepia (n=44) ou un placebo identique (n=44) et les sujets ont été suivis pendant six mois pour évaluer les résultats cliniques prédéfinis. Le premier indicateur de résultat a été le changement des plaintes liées à la ménopause évaluées à l'aide de la grille 'Greene Climacteric Scale' (GCS) et le deuxième indicateur de résultat a été le changement de la qualité de vie évalué à l'aide de la grille 'Utian Quality of Life Scale' (UQOL). Résultats : 88 patientes ont été considérées pour l'analyse du premier indicateur de résultat. Le premier indicateur de résultat, à savoir le score total de GCS, comparé après 6 mois, avait réduit de 30,23 ± 8,1 à 7,86 ± 4,6 dans le groupe Sepia (amélioration de 73,9 %) et de 30,05 ± 8,9 à 12,73 ± 8,3 dans le groupe placebo (amélioration de 57,63 %) (p = 0,001). Il y avait une différence statistiquement significative entre les deux groupes après six mois (p = 0,001). En ce qui concerne le deuxième indicateur de résultat, le score UQoL total était de 59,09 ± 7,74 pour le groupe Sepia et de 57,39 ± 7,80 pour le groupe placebo au départ, et de 62,43 ± 7,71 pour le groupe Sepia et de 63,48 ± 7,53 pour le groupe placebo à la fin, indiquant une légère différence de qualité de vie après six mois. Conclusion : Le médicament Sepia arrive à soulager les symptômes de la ménopause lorsqu'il est prescrit sur des indications symptomatiques selon les principes homéopathiques.
